Results from Swedish multi-centre clinical trial with follow-up of 30 Episealer® patients accepted for scientific publication
Episurf Medical (Nasdaq: EPIS B) today announces that results from a clinical study with follow-up of the 30 first Episealer® patients from nine Swedish clinics has been accepted for publication in the scientific journal Cartilage. The publication is expected to be available online shortly. The study reports on good implant safety and significantly improved patient-reported outcome scores. In total, 30 patients are included in the study and the average follow-up time is 55 months (subjective outcome scores at 24 months, survival data at 24 – 86 months, mean of 55 months). The Episealer®